Learn More
Treatment Guidance
Vectra scores over time help inform the success of treatment and the impact of therapy on disease control.
Change in score is related to the Minimally Important Difference (MID) for Vectra. The MID is the smallest absolute change in Vectra score that is likely to reflect change in disease activity and not be due only to random variation. The MID for patients with a moderate or high Vectra score is 8. This MID does not apply for patients with a low Vectra score. Treatment guidance recommendations should be interpreted in the context of all available clinical information.
Case Studies
Patient Care with a Single Vectra Test
An evaluation that combines a molecular measure of biomarkers along with a patient assessment and physician assessment provides the most comprehensive disease activity measurement. A Vectra test provides that molecular insight.
Discordance in Patient and Provider Assessments
What if the patient’s assessment does not match yours? Patient-Provider discordance in RA disease assessment happens as much as 33% of the time. Vectra provides an objective, personalized molecular measure.
Better Outcomes for a Stoic Patient
There is a gap between a patient’s day-to-day experience of RA and the clinical assessment by which physicians evaluate disease activity and inflammation. In fact, 2 out of 3 patients living with smoldering RA disease say that they feel good. Vectra helps identify patients that may need a change or increase in treatment therapy.
Vectra Guided Care
Vectra can help improve patient outcomes when added to other assessments. A meaningful change of 8 or more units in subsequent Vectra scores indicates a change in RA disease activity and inflammation for patients with moderate and high Vectra scores.
Patient-Provider Discordance, Fibromyalgia
Patient Hesitant To Start Biologic Therapy
Discordance Between Patient & Provider Assessment #2
ORDER CLINICAL SUMMARIES
Order Vectra